Key result
Enoxaparin compared with unfractionated heparin in acute coronary syndromes reduced the net clinical endpoint of death, MI, or major bleeding at 30 days.
Why the study?
Does enoxaparin improve net clinical outcomes compared to unfractionated heparin in patients with acute coronary syndromes?
Meta-Analysis (n=49,088)
Yes
Does enoxaparin improve net clinical outcomes compared to unfractionated heparin in patients with acute coronary syndromes?
Enoxaparin provides a net clinical benefit over unfractionated heparin in STEMI patients, driven by reduced death or MI despite increased bleeding, but has a neutral net effect in NSTEACS.
Answers are grounded in this paper and cite their sources.
Supports borderline net benefit with enoxaparin in ACS; extends meta-evidence by balancing ischemic and bleeding outcomes across subgroups.
AIMS: To determine whether the low-molecular weight heparin enoxaparin remains favourable when compared with unfractionated heparin (UFH) among patients with acute coronary syndromes (ACS) when incorporating efficacy and safety of these adjunctive therapies using a net clinical endpoint. METHODS AND RESULTS: We performed a meta-analysis of randomized trials of enoxaparin vs. UFH in ST-elevation-MI (STEMI) or non-ST-elevation-ACS (NSTEACS) (n = 49,088 patients in 12 trials). The net clinical endpoint was defined as death, MI, or major bleeding by 30 days. Death or myocardial infarction (MI) was significantly reduced with enoxaparin when compared with UFH (9.8 vs. 11.4%, OR 0.84, P < 0.001). The net clinical endpoint occurred less frequently with enoxaparin than UFH (12.5 vs. 13.5%, OR 0.90, P = 0.051). Major bleeding was higher with enoxaparin (4.3 vs. 3.4%, OR 1.25, P = 0.019). Among STEMI trials, the net clinical endpoint was significantly lower with enoxaparin (OR 0.84, P = 0.015), but there was no difference in NSTEACS trials (OR 0.97). CONCLUSIONS: When compared with UFH, enoxaparin was associated with superior efficacy as adjunctive antithrombin therapy among >49 000 patients across the ACS spectrum. Although bleeding was increased with enoxaparin, this increase was offset by a reduction in death or MI. The net clinical benefit in favour of enoxaparin was evident among the STEMI population and was neutral among the NSTEACS population.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2007) conducted a meta-analysis in acute coronary syndromes (ACS) (n=49,088). enoxaparin vs. unfractionated heparin (UFH) was evaluated on net clinical endpoint (death, MI, or major bleeding by 30 days) (OR 0.90, p=0.051). Enoxaparin compared with unfractionated heparin in acute coronary syndromes reduced the net clinical endpoint of death, MI, or major bleeding at 30 days.
Synapse has enriched 10 related papers. Consider them for comparative context: